108 Relationship between PAI-1 promoter polymorphism and PAI-1 circulating levels in postmenopausal women with coronary artery disease (CAD)

Grancha, Salvador; Estellés, Amparo; Gilabert, J.; Tormo, Guillermo Sáez; Falcó, Cristina; España, Francisco; Aznar, J.J.

doi:10.1016/s0268-9499(97)80224-x

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of effect of the 4G/5G genotype contrasts a previously published study by Grancha et al 42 In that study, the authors reported a significantly greater decrease in PAI-1 antigen in response to transdermal estrogen in women with coronary artery disease (CAD) who were either homozygous or heterozygous for the PAI-1 4G allele compared with those who were homozygous for the 5G allele. Estrogen significantly reduced PAI-1 in this study, even though it was administered transdermally, in contrast to several other studies.…”

Section: Discussioncontrasting

confidence: 64%

Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women

et al. 2002

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 64%

Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Elevated levels of PAI-1 have been associated with increased cardiovascular risk and increased thrombogenic tendency [25][26][27]. The higher prevalence of homozygosity 4G/4G and heterozygosity 4G/5G population and its association with higher PAI-1 levels may further increase the cardiovascular risks in this population of young women, as it has been reported in patients who suffer from coronary heart disease [11], venous thromboembolism [27] or type 2 diabetes mellitus [28,29].…”

Section: Discussionmentioning

confidence: 99%

4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome

Karadeniz

Erdoğan

Berdelı

et al. 2007

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Polycystic ovary syndrome (PCOS) is one of the most encountered endocrine malfunctions. PCOS patients have enhanced activation of the blood coagulation system. Methods Eighty-six young women with PCOS and 70 healthy control women were included in our study. PCOS patients and controls were matched for age, body mass index, and allele frequency. Genetic analysis of TPAI and PAI-1 were performed in all subjects. Results and conclusions No statistically significant differences have been detected about the ratios of genotypes resulting from PAI-1 promotor 4G/5G gene polymorphism. PAI-1 765 4G/5G gene polymorphism and TPA gene's Alurepeat insertion/deletion (I/D) polymorphism ratios were not different from the controls. In this study it is shown by the analysis of TPA gene's Alu-repeat insertion/deletion (I/D) polymorphism the PCOS patients with genotype II had lowers total cholesterol and LDL-cholesterol levels.

show abstract

“…It is known that an increased PAI-1 concentration induces decreased plasmin formation and leads to an accumulation of fibrin. The 4G allele and the 4G/4G genotype of PAI-1 have been reported to be associated with increased basal gene transcription, and consequently have been regarded as thrombogenic factors (21,24,26,27). With this kept in mind, our results are suggestive of some other role of PAI-1 in the process of rebleeding, except the effect on fibrinolytic activity.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, the 4G allele of the PAI-1 gene is associated with increased basal gene transcription. The 4G/4G genotype of PAI-1 has been shown to be associated with ischemic heart disease (24,26) and myocardial infarction (MI) (21,27).…”

Section: Introductionmentioning

confidence: 99%

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 Gene Polymorphism in Patients with Gastric Ulcer Complicated with Bleeding

et al. 2003

View full text Add to dashboard Cite

Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) may be involved in the pathogenesis of peptic ulcers through suppression of fibrinolysis. This study was designed to investigate associations of t-PA and PAI-1 genes with clinical features of the patients with bleeding gastric ulcers. Eighty-four patients with peptic ulcers and 100 controls were studied between January 1998 and April 2000. We used polymerase chain reaction and endonuclease digestion to genotype for 4G/5G polymorphism in the promoter region of the PAI-1 gene and the Alu-repeat insertion/deletion (I/D) polymorphism in intron h of the t-PA gene. Various clinical features, including lesion site, bleeding event, recurrence of ulcer, and rebleeding, were assessed using a multiple logistic regression model. The genotype distributions of both the t-PA and PAI-1 genes did not differ between the patient and control groups. The occurrence of the I/D or D/D genotype of t-PA was significantly higher in cases of duodenal ulcer (adjusted OR=4.39, 95% CI=1.12-17.21). When a dominant effect (i.e., 4G/4G or 4G/5G versus 5G/5G) of the 4G allele was assumed, the PAI-1 4G/ 4G genotype was independently associated with rebleeding after hemostasis (adjusted OR=5.07, 95% CI=1.03-24.87). Our data suggest that t-PA gene polymorphism is associated with duodenal ulcers, and that the PAI-1 gene may be a risk factor leading to recurrent bleeding after initial hemostasis.

show abstract

108 Relationship between PAI-1 promoter polymorphism and PAI-1 circulating levels in postmenopausal women with coronary artery disease (CAD)

Cited by 4 publications

References 0 publications

Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women

Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women

4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 Gene Polymorphism in Patients with Gastric Ulcer Complicated with Bleeding

Contact Info

Product

Resources

About